Vital Therapies closes $28.1m round:
This article was originally published in Clinica
Executive Summary
Manufacturer of the ELAD (extracorporeal liver assist device) artificial liver Vital Therapies (VTI) has completed a $28.1m series C financing round. The round, which was led by Versant Ventures, will support the San Diego, California-based company's development of what it claims to be the world's only human cell-based artificial liver. The firm is preparing to file for marketing approval of ELAD in China, and advance its US clinical programme of the product. The financing included the participation of new investors Delphi Ventures, HBM BioMed China and DFJ DragonFund China, and existing shareholders MedVenture Associates, Valley Ventures, Toucan Capital and Heights Capital. The financing sees Versant Ventures' Dr Ross Jaffe join the VTI board of directors.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.